Orthopedic Regenerative Surgical Products Market Size & Share, by Product (Allografts, Synthetic, Cell-based, Viscosupplements); Application; End use - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

North America Market Analysis

North America in orthopedic regenerative surgical products market is expected to hold over 42% revenue share by the end of 2037. The region’s healthcare infrastructure is fully equipped with high-tech accommodations and adequate distribution channels. Additionally, the presence of global players is propelling regional expansion. For instance, in September 2023, Anika Therapeutics introduced its RevoMotion Reverse Shoulder Arthroplasty System (RSA) at the annual event of Orthopaedic Summit (OSET) 2023. The new extension of the reverse shoulder portfolio contains a small-diameter threaded baseplate, which prevents bone degeneration and maximizes flexibility, solidifying its position in U.S. market.

The U.S. market is augmented by the integration of automation and bio-engineering into the surgical practice. In addition, the favorable regulatory framework of the country is impelling the reach of this category by allowing innovative solutions in the orthopedic industry. Such a progressive atmosphere in this marketplace is further encouraging leaders from various related segments to engage their resources. For instance, in August 2023, 3D Systems partnered with Theradaptive to curate novel approaches toward bone and tissue reconstruction. The commercial collaboration was intended to maximize advancements in healing and repairing through the joint development of protein-based material-binding variants coated 3D-printed medical devices.

The rising cases of osteoporosis in Canada are the prominent propellor of the orthopedic regenerative surgical products market. According to the Canadian Chronic Disease Surveillance System (CCDSS), around 2.5 million citizens aged 40 and over were diagnosed with osteoporosis between 2019 and 2020. The statistics further revealed that this figure is expected to double every 5 years for the same age-standardized epidemiology, with a heightened risk of serious bone fracture. Thus, the governing bodies of the country are being pushed to take immediate action to combat the widespread. For instance, in September 2020, the government of Canada, in collaboration with Orthopaedic Innovation Centre, allocated funding of USD 399,647 to empower domestic medical devices and specialized equipment supply chain.

APAC Market Statistics

The Asia Pacific orthopedic regenerative surgical products market is anticipated to showcase significant progress during the assessed timeline. The magnifying volume of geriatric habitats in this region is also a major contributor to this field. According to the Asian Development Bank, the number of people over 60 in Asia and Asia Pacific is poised to reach 1.3 billion by 2050. The emphasized bioeconomy and growing awareness about the cost-effectiveness of this technique are feeding propagation in this category. In addition, its strong emphasis on the utilities of biomaterials in healthcare signifies a lucrative marketplace for global leaders. According to a Research Nester report, the APAC orthopedic biomaterials industry is estimated to capture the largest share of 41.0% during the forecasted timeframe.

India, with its enlarging MedTech industry, is propagating the orthopedic regenerative surgical products market with greater investment opportunities. The government’s ambitious goals and initiatives such as Made in India to strengthen in-house production of medical devices and instruments are cultivating a potential to lead the current international scenario. For instance, in June 2024, Meril launched a surgical robotic system, MISSO to offer surgeons assistance during knee replacement surgeries. It is one of those domestically developed devices, which can offer exceptional cost-effectiveness, 66.0% less expensive compared to other tools. Such cost-effective solutions are increasing accessibility in the market.

China is expanding its territory in the orthopedic regenerative surgical products market with its remarkable clinical discoveries and manufacturing capabilities. The increasing public-private collaborations are empowering the country’s capacity of producing these products. This also inspires other players of this sector to establish their network in China, enabling a good flow of business. Furthermore, the increased cases of OA across the country are inflating the need for procedures associated with reconstruction. According to the NLM report, published in December 2022, the amount of hip or knee arthroplasties in China were reported to be 50,000 each year, exhibiting an annual increment of over 15.0%. The emphasizing figures are evidence of the inflation in urge for related surgical tools.